Determinants for progression from asymptomatic infection to symptomatic visceral leishmaniasis: A cohort study
A prospective study in two high VL incidence areas of Muzaffarpur district, Bihar State, India from 2008–2015 was conducted with resident subjects. The study aimed at identifying markers for progression from L. donovani infection to clinical Visceral Leishmaniasis (VL). Both high DAT and/or rK39 titers were associated with progression to disease and qPCR was identified as an additional predictor. The authors also recommend that asymptomatic individuals with low predictive values are carefully observed for at least 6 months after testing.
Treatment outcomes of visceral leishmaniasis in Ethiopia from 2001 to 2017: a systematic review and meta-analysis
A systematic review of 15 studies examining VL treatment outcomes at end of treatment and at 6 months follow-up in Ethiopia.
Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia
A prospective cohort study conducted in Northwest Ethiopia from August 2014 to August 2017 examined long-term treatment outcomes of visceral leishmaniasis (VL) patients with HIV co-infection, who are at high rate of relapse. HIV-VL patients were followed for up to 12 months with their CD4 counts were monitored. The study concludes that "patients with relapsed VL are at higher risk for subsequent relapse and should be considered a priority for secondary prophylaxis, irrespective of their CD4 count".
Review of the current diagnostic and treatment tools used for the management of visceral leishmaniasis.
This paper reviews recent progress for VL control measures and identifies priority areas to reach the 2020 VL elimination target in the South Asian region.
Barriers of Visceral Leishmaniasis reporting and surveillance in Nepal: comparison of governmental VL‐program districts with non‐program districts
A cross‐sectional mixed‐method study on populations from districts targeted by the national VL programme and non‐program districts. The researchers describe delays to health-seeking, to diagnosis and to treatment in the two populations and identify barriers to access in Nepal.
A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia
Human antibody reaction against recombinant salivary proteins of Phlebotomus orientalis in Eastern Africa
Study that aimed at uncovering valid markers of human exposure to vector sanfly P. orientalis order to help monitor the distribution of the VL vector and shape anti-vector interventions. The researchers "screened for anti-P. orientalis antibody responses in serum samples from individuals residing in Sudan and Ethiopia".
Integrating Case Detection of Visceral Leishmaniasis and Other Febrile Illness with Vector Control in the Post-Elimination Phase in Nepal
Following the completion of the attack phase of visceral leishmaniasis elimination Nepal is now entering the the consolidation and maintenance phases.This study evaluated different ACD approaches and vector control methods in Nepal. It highlights fever camps and insecticidal wall paint as potential sustainable strategies in the VL post-elimination program.
Amphotericin B deoxycholate for relapse visceral leishmaniasis in Bangladesh: a cross-sectional study
Cross-sectional study on 34 VL relapse patients reviewing the cure rate and adverse effects to amphotericin B deoxycholate in Bangladesh. The study supports the use of amphotericin B deoxycholate as a second line drug for visceral leishmaniasis in Bangladesh.